Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00137995 · ClinicalTrials.gov registry record · Phase 3
R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma
A Phase 3 study of Lymphoma, Large-Cell, Diffuse, sponsored by Lymphoma Study Association.
- Completed
- Registry status
- Phase 3
- Development phase
- 481
- Enrollment target
- 10
- Study locations
NCT00137995: Completed Phase 3 study of Lymphoma, Large-Cell, Diffuse, sponsored by Lymphoma Study Association.
NCT00137995 is a Phase 3 study of Lymphoma, Large-Cell, Diffuse that has completed, run by Lymphoma Study Association. The registered enrollment target is 481 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (38% lower). The trial reports 10 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00137995, a Phase 3 study of Lymphoma, Large-Cell, Diffuse, has completed, sponsored by Lymphoma Study Association.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 481 participants
- Enrollment target
- 10
- Study locations
Study Summary
The primary objective of this study is to evaluate the efficacy and safety of induction therapy R-ICE in comparison to R-DHAP after 3 cycles adjusted to successful mobilization of stem cells in patients with previously treated diffuse large B-cell lymphoma CD20. The goal is to detect a difference in mobilization adjusted response rate of 15% between R-ICE and R-DHAP. The other objective is to evaluate the efficacy and safety of MabThera maintenance therapy after transplantation as measured by the event free survival. The goal is to obtain a 15% increase of event free survival at 2 years.
Conditions Studied
Interventions
- DRUG Rituximab
- DRUG Etoposide
- DRUG Carboplatine
- DRUG Ifosfamide + Mesna
- DRUG Cisplatine
Study Locations (10)
Other
- Australian leukemia and lymphoma group - Sydney
- Groupe d'atude des lymphome de l'adulte - Yvoir
- Czech Lymphoma study group - Prague
- Hospital district of south west Finland - Turku
- German high grade non hodgkin's lymphoma group - Hamburg
- Israel Society of Hematology - Tel Litwinsky
- Nordic center - Uppsala
- Schweirische Arbeitsgruppe fur klinische Krebsforschung - Lausanne
- National cancer research institute - London
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 481 participants |
| Start Date | 2003-06 |
| Est. Completion | 2008-10 |
| Phase | Phase 3 |
What the finished NCT00137995 record still lists
NCT00137995 is an interventional study that assigns participants to a tested intervention. The registered 481 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (38% lower).
The record links to 1 condition, with Lymphoma, Large-Cell, Diffuse appearing as the primary indexed condition, and to 5 interventions - of which Rituximab is the first listed.
NCT00137995 lists 10 locations in 2 states (Other, New York).
Frequently Asked Questions
What is clinical trial NCT00137995 about?
NCT00137995 is a clinical study titled "R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma". The primary objective of this study is to evaluate the efficacy and safety of induction therapy R-ICE in comparison to R-DHAP after 3 cycles adjusted to successful mobilization of stem cells in patients with previously treated diffuse large B-cell lymphoma CD20. The goal is to detect a difference i...
What is the current status of trial NCT00137995?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 481 participants. The study started on 2003-06. Estimated completion is 2008-10.
What conditions does trial NCT00137995 study?
This clinical trial studies the following conditions: Lymphoma, Large-Cell, Diffuse.
What interventions are being tested in trial NCT00137995?
The interventions under investigation include: Rituximab (DRUG), Etoposide (DRUG), Carboplatine (DRUG), Ifosfamide + Mesna (DRUG), Cisplatine (DRUG).
Who is sponsoring clinical trial NCT00137995?
This trial is sponsored by Lymphoma Study Association, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00137995 being conducted?
This trial has 10 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00137995's enrollment target sits among peer trials
481 792nd of 2000 higher than 1,209 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04449458 · 482 participants · NA
The Positively Quit Trial for Smoking Cessation
- NCT07079631 · 482 participants · Phase 1
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
- NCT01954992 · 480 participants · Phase 3
Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
- NCT03023696 · 480 participants · NA
Can Prophylactic Foraminotomy Prevent C5 Palsy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia